These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22046967)

  • 21. Serious Opportunistic Lower Respiratory Tract Infections in Pediatric Rheumatic Diseases During Treatment With Biologics.
    Ogstrup AK; Spannow AH; Holm M; Rubak S; Veirum JE; Glerup M; Herlin T
    J Clin Rheumatol; 2021 Dec; 27(8S):S387-S391. PubMed ID: 32694355
    [No Abstract]   [Full Text] [Related]  

  • 22. Treat-to-target biologic therapy in patients with rheumatoid arthritis is more efficacious and safe compared to delayed initiation of biologics: a real-world study.
    Lampropoulos CE; Orfanos P; Manoussakis MN; Tzioufas AG; Moutsopoulos HM; Vlachoyiannopoulos PG
    Clin Exp Rheumatol; 2017; 35(2):192-200. PubMed ID: 28094760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of cardiovascular risk factors].
    Krüger K
    Z Rheumatol; 2016 Mar; 75(2):173-80; quiz 181-2. PubMed ID: 26924198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
    Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
    Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The first biologic for rheumatoid arthritis: factors influencing the therapeutic decision].
    Pattloch D; Richter A; Manger B; Dockhorn R; Meier L; Tony HP; Zink A; Strangfeld A
    Z Rheumatol; 2017 Apr; 76(3):210-218. PubMed ID: 27518855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune-mediated inflammatory disease patients' preferences in adverse drug reaction information regarding biologics.
    Kosse LJ; Weits G; Vonkeman HE; Spuls PI; Van Den Bemt BJF; Tas SW; Hoentjen F; Nurmohamed MT; Van Doorn MBA; Van Puijenbroek EP; Jessurun NT
    Expert Opin Drug Saf; 2020 Aug; 19(8):1049-1054. PubMed ID: 32524887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction or cessation of antiviral agents in hepatitis B virus carriers treated with biologic agents.
    Ghang B; Lee D; Hwang I; Lee CK; Yoo B; Kim YG
    Clin Exp Rheumatol; 2018; 36(1):170. PubMed ID: 29352838
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers.
    Shimada H; Kameda T; Kanenishi K; Miyatake N; Nakashima S; Wakiya R; Kato M; Miyagi T; Mansour MMF; Hata T; Kadowaki N; Dobashi H
    Clin Rheumatol; 2019 May; 38(5):1453-1458. PubMed ID: 30729372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study.
    Lampropoulos CE; Orfanos P; Bournia VK; Karatsourakis T; Mavragani C; Pikazis D; Manoussakis MN; Tzioufas AG; Moutsopoulos HM; Vlachoyiannopoulos PG
    Clin Exp Rheumatol; 2015; 33(2):216-24. PubMed ID: 25664400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.
    George MD; Baker JF; Winthrop K; Alemao E; Chen L; Connolly S; Hsu JY; Simon TA; Wu Q; Xie F; Yang S; Curtis JR
    Ann Intern Med; 2019 Jun; 170(12):825-836. PubMed ID: 31108503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
    Chiu YM; Chen DY
    Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
    Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
    Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The British Society for Rheumatology biologics register.
    Watson K; Symmons D; Griffiths I; Silman A
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv42-3. PubMed ID: 16239385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.
    Hadjinicolaou AV; Nisar MK; Bhagat S; Parfrey H; Chilvers ER; Ostör AJ
    Rheumatology (Oxford); 2011 Dec; 50(12):2297-305. PubMed ID: 22019799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Rheumatic diseases during pregnancy].
    Fischer-Betz R
    Internist (Berl); 2012 Sep; 53(9):1047-53. PubMed ID: 22695896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
    Michelena X; Borrell H; López-Corbeto M; López-Lasanta M; Moreno E; Pascual-Pastor M; Erra A; Serrat M; Espartal E; Antón S; Añez GA; Caparrós-Ruiz R; Pluma A; Trallero-Araguás E; Barceló-Bru M; Almirall M; De Agustín JJ; Lladós J; Julià A; Marsal S
    Semin Arthritis Rheum; 2020 Aug; 50(4):564-570. PubMed ID: 32425260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Respiratory pathogen spectrum in pulmonary exacerbation of bronchiectasis in adults and its association with disease severity].
    Gao YH; Guan WJ; Zhu YN; Chen RC; Zhang GJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Apr; 42(4):254-261. PubMed ID: 30955282
    [No Abstract]   [Full Text] [Related]  

  • 40. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.
    Cantini F; Niccoli L; Capone A; Petrone L; Goletti D
    Expert Opin Drug Saf; 2019 May; 18(5):415-425. PubMed ID: 31066297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.